Biocatalytic Routes to Enantiomerically Enriched Dibenz[*c*,*e*]azepines

Scott P. France,[a] Godwin A. Aleku,[a]  Mahima Sharma,[b] Juan Mangas-Sanchez,[a] Roger M. Howard,[c,d] Jeremy Steflik,[c] Rajesh Kumar,[c] Ralph W. Adams,[e] Iustina Slabu,[a] Robert Crook,[d] Gideon Grogan,[b] Timothy W. Wallace,[e] and Nicholas J. Turner\*[a]

[a] S. P. France, Dr. G. A. Aleku, Dr. J. Mangas-Sanchez, I. Slabu, Prof. N. J. Turner  
School of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, UK.  
E-mail: nicholas.turner@manchester.ac.uk

[b] Dr. M. Sharma, Prof. G. Grogan   
York Structural Biology Laboratory, Department of Chemistry, University of York, Heslington, York, YO10 5DD UK.

[c] Dr. R. M. Howard, Dr. J. Steflik, Dr. R. Kumar

Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut, 06340, US.

[d] Dr. R. M. Howard, Dr. R. Crook

Sandwich Laboratories, Pfizer Worldwide Research and Development, Discovery Park, Sandwich, Kent, CT13 9NJ, UK.

[e] Dr. R. W. Adams, Dr. T. W. Wallace

School of Chemistry, University of Manchester, Manchester M13 9PL, UK.

Supporting information for this article is given *via* a link at the end of the document.

***Abstract:*** *Biocatalytic retrosynthetic analysis of dibenz[c,e]azepines has highlighted the use of imine reductase (IRED) and transaminase (-TA) biocatalysts to establish the key stereocentres. Several enantiocomplementary IREDs were identified for the synthesis of (R)- and (S)-5-methyl-6,7-dihydro-5H-dibenz[c,e]azepine with excellent enantioselectivity by reduction of the parent imines. Crystallographic evidence suggests that IREDs may be able to bind one conformer of the imine substrate such that, upon reduction, the major product conformer is generated directly. ω-TA biocatalysts were also successfully employed for the production of enantiopure 1-(2-bromophenyl)ethan-1-amine enabling an orthogonal route for the installation of chirality into dibenz[c,e]azepine frameworks.*

Dibenz[*c*,*e*]azepines belong to a class of privileged bridged biaryl frameworks that possess unique conformational features. These architectures feature in several bioactive compounds, such as anti-obesity drugs[1] and analogues of the alkaloid colchicine,[2] as well as providing key structural elements in chiral organocatalysts[3,4] and chiral bases[5] (Figure 1a). Dibenz[*c*,*e*]azepines can also act as molecular switches, owing to the conformational influence of C-centred chirality on the azepine ring with the axial chirality of the system. In their lowest energy conformation, substituents at the C(5) or C(7) position of the azepine ring are found to occupy a pseudo-equatorial position, imparting a particular conformation of the biaryl axis. Therefore, setting the C-centred chirality during the synthesis of these compounds also establishes the preferred biaryl conformation. If the C(5) or C(7) substituent is perturbed from a pseudo-equatorial to a pseudo-axial position, for example after *N*-derivatisation, a resulting switch in axial chirality occurs *via* this centre-axis relay effect (Figure 1b).[6]

Enantiomerically pure dibenz[*c*,*e*]azepines have previously been synthesised by employing chiral pool starting materials,[5,7] chiral auxiliary methodology[6,8,9] or chiral transition metal catalysis[10] employing synthetic routes identified by traditional disconnection strategies. In order to identify new and potentially more efficient routes to these compounds, we sought to apply the principles and continually expanding scope of biocatalytic retrosynthesis.[11–13]



**Figure 1.** Dibenz[*c*,*e*]azepine architectures. a) Dibenz[*c*,*e*]azepine frameworks found in active pharmaceutical ingredients, natural product analogues, organocatalysts and reagents in organic synthesis. b) Dibenz[*c*,*e*]azepine acting as a molecular switch with the axial conformation inverting upon *N*-Boc derivatisation.

The suite of biocatalysts available for the asymmetric synthesis of chiral amines currently includes ω-transaminases (ω-TAs),[14–17] imine reductases (IREDs),[18–21] reductive aminases (RedAms),[22] amine dehydrogenases (AmDHs)[23,24] and ammonia lyases[25] as well as hydrolases[26,27] and monoamine oxidases (MAOs)[28–30] for (dynamic) kinetic resolution or deracemisation procedures respectively.

With this toolbox of enzymes in mind, we initially envisaged setting the C(5) stereogenic centre of the dibenz[*c*,*e*]azepine framework by employing an IRED in the final step (Figure 2). IREDs catalyse the NADPH-dependent asymmetric reduction of prochiral imines to afford chiral amines and have been applied to the synthesis of a range of chiral pyrrolidines and piperidines.[31–35] Recently, a sub-group of the IRED family, known as RedAms,[22] has been identified and shown to catalyse imine formation as well as imine reduction in reductive amination reactions of carbonyl compounds, although RedAms can also catalyse the reduction of preformed cyclic imines. The imine substrate **1** for the IRED mediated reduction could be derived from the corresponding Boc-protected amino ketone **3** which could itself be made *via* a Suzuki-Miyaura cross-coupling of aryl boronic acid **4** and aryl bromide **5**. Furthermore, we envisaged preparing the chiral amine **5** using an ω-TA biocatalyst. ω-TAs are pyridoxal-5’-phosphate (PLP)-dependent enzymes that transfer an amino group from an amine donor, such as isopropylamine (IPA) or alanine, to a carbonyl compound. Transaminase-catalysed reactions are in equilibrium and often need to be driven to completion either using an excess of amine donor, co-product removal strategies or ‘smart’ amine donors, all of which perturb the equilibrium in favour of product.[14]



**Figure 2.** A biocatalytic retrosynthetic approach to the synthesis of **2** incorporating IRED and ω-TA biocatalysts.

The planned forward synthesis was carried out by preparing four model imine substrates **1a**-**d** that varied at R1 and R2 by H or Me. Suzuki-Miyaura coupling of boronic acids **4i-ii** and *N*-Boc aryl bromides **5i**-**ii** catalysed by Pd(amphos)Cl2 successfully afforded biaryls **3a**-**d**. Subsequent Boc deprotection by trifluoroacetic acid (TFA) and spontaneous intramolecular condensation furnished imines **1a**-**d** which were isolated as their hydrochloride salts (Table 1). Compounds **1a**, **1c** and **1d** possess axial chirality and 1D selective EXSY experiments of **1a** in D2O revealed a half-life to axis inversion of 1.7 ± 0.4 seconds at 298 K with an energy barrier of 75.2 ± 0.5 kJ mol-1 (see Supporting Information). Therefore, at room temperature there is fast interconversion between atropisomers.

The panel of imine substrates **1a**-**d** was then screened with a library of 49 IREDs[36,37] including three from the recently described fungal RedAm sub-group[22]; *Asp*RedAm from *Aspergillus oryzae*, *Ad*RedAm from *Ajellomyces dermatitidis* and *At*RedAm from *Aspergillus terreus*. Biotransformation results showed that imine substrates **1a** and **1b**, when reduced by an IRED, typically gave high conversions (Table 2). Interestingly, in the reduction of **1a**, the fungal RedAms and the IRED from *Amycolatopsis orientalis* (*Ao*IRED)[37] gave the (*R*)-configured product while the other bacterial IREDs screened displayed opposite enantioselectivity with excellent *ee*. For substrate (±)-**1c**, the ability of the IREDs to perform a kinetic resolution by reducing a single enantiomer of this compound was assessed, however, this substrate proved to be generally more challenging with typically lower conversions, modest product *ee*s and *E* values <5 observed in each case. Unfortunately, substrate (±)-**1d** showed little to no conversion across all the wild-type enzymes screened.

**Table 1**. Synthesis of imines **1a**-**d**



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entry | R1 | R2 | Yield of **3** [%] | Yield of **1** [%] |
| 1 | Me | H | **3a**, 95 | **1a**, 87 |
| 2 | Me | Me | **3b**, -[a] | **1b**, 52[b] |
| 3 | H | Me | **3c**, -[a] | **1c**, 63[b] |
| 4 | H | H | **3d**, -[a] | **1d**, 69[b] |

[a] Impure after several rounds of column chromatography therefore isolated yield given after the next step. [b] Yield over two steps from **5** as limiting reagent.

**Table 2**. Highlighted best performing enzymes from IRED screen with substrates **7a**-**d**.



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Conversion of substrate/%, *ee*/% (*R* or *S*) | | | |
| Enzyme | **1a** | **1b** | **1c** | **1d** |
| *Asp*RedAm | >99, >99 (*R*) | 98 | 5 | 0 |
| *Ad*RedAm | >99, >99 (*R*) | >99 | 41, 16 (*R*) | 1 |
| *At*RedAm | 6, 52 (*R*) | 25 | 27, 57 (*R*) | 0 |
| *Ao*IRED | 51, >99 (*R*) | 5 | <1 | 0 |
| IR52 | 94, >99 (*S*) | >99 | 26, 29 (*R*) | 0 |
| IR55 | >99, >99 (*S*) | 76 | 32, 6 (*S*) | 0 |
| IR62 | 45, >99 (*S*) | >99 | 38, 6 (*S*) | 1 |
| IR67 | 99, >99 (*S*) | 94 | 5 | 0 |
| IR86 | 99, >99 (*S*) | >99 | 82, 11 (*R*) | 0 |
| IR89 | >99, >99 (*S*) | >99 | 80, 27 (*R*) | 0 |
| IR91 | >99, >99 (*S*) | >99 | >99, 0 | 1 |
| IR92 | 97, >99 (*S*) | >99 | 8 | 0 |
| IR93 | 64, >99 (*S*) | 59 | 4 | 0 |

Reaction conditions: 5 mM **1**, 20% v/v cell lysate (equivalent to 50 mg/mL wet cell weight final concentration), 0.3 mg/mL glucose dehydrogenase CDX-901 (GDH), 50 mM glucose, NADP+ (0.4 mM), 100 mM NaP*i* buffer, pH 7.5, 25°C, 250 rpm, 24 h. Conversion and *ee* determined by HPLC or GC-FID analysis on a chiral phase.

Preparative-scale reactions with **1a** were successfully performed with *Asp*RedAm and IR91 to isolate opposite enantiomers of **2a** in high conversion, yield and enantioselectivity, demonstrating the synthetic utility of this biocatalytic approach (Scheme 1). Product NMR spectra were identical to those previously reported,[6,7] confirming the predominant conformers as (*R*,a*S*)-**2a** and (*S*,a*R*)-**2a** respectively, which are governed by thermodynamic equilibration between the atropisomers (86:14 major:minor at 298K).[6] As the conformers of imine **1a** can interconvert rapidly, it is possible the enzymes can carry out a dynamic kinetic resolution process in which a single atropisomer of the imine is converted to the major product atropisomer (Scheme 1, Path A). However, we cannot rule out whether the enzymes can reduce the imine conformer that would lead to the minor atropisomer (Scheme 1, Path B).



**Scheme 1.** Preparative-scale biotransformations to afford opposite enantiomers of **2a** employing *Asp*RedAm and IR91. A dynamic kinetic resolution process could occur in which a single imine conformer is reduced to the major product atropisomer (A) although path B may also occur. The same process is envisaged to occur for the reaction with IR91 which is not shown in full for brevity.

A crystal structure of *At*RedAm, which has a closely related active-site to *Asp*RedAm, in complex with the imine substrate **1a** was successfully obtained through co-crystallisation with the redox inactive cofactor analogue NADPH4. Interestingly, although the ligand is not bound in a mode that positions the electrophilic imine carbon atom close to the C4 atom of the cofactor analogue, the structure suggests that these enzymes may be able to selectively bind a single conformer of the biaryl imine **1a** from a rapidly equilibrating mixture. Furthermore, this conformer, (a*S*)-**1a**, would lead directly to the lowest energy conformation of the product (*R*,a*S*)-**2a** upon reduction (Figure 3).

Wild-type *Asp*RedAm and *Ao*IRED gave poor conversions of (±)-**1c** and (±)-**1d**, therefore mutagenesis was explored in attempts to improve activity towards these substrates. Analysis of the ligand binding site as revealed by the ternary structure of *At*RedAm (Figure 3) and a sequence alignment with *Asp*RedAm and *Ad*RedAm highlighted the following conserved residues; (A)D175, (B)W215, (B)M219 and (B)Q245 [(A)D169, (B)W210, (B)M214 and (B)Q240 in *Asp*RedAm respectively] that may play important roles in substrate binding and recognition. We therefore generated and screened *Asp*RedAm site-directed mutants D169A, D169N, W210A, W210S, M214A and Q240A, in an attempt to open up the active site to allow these bulkier substrates to bind. Of these mutants, only the Q240A variant afforded significantly improved conversion of (±)-**1c** (67%)**,** although with low enantioselectivity (7%, *S*). Furthermore, this variant was able to convert substrate (±)-**1d** in contrast to the wild-type (8% *vs* 0%).

****

**Figure 3**: Active site of *At*RedAm in complex with substrate **1a** and the inactive cofactor NADPH4. The active site is formed at the dimer interface between monomers A (light blue) and B (gold). Electron densities correspond to the *Fo*-*Fc* and 2*Fo*-*Fc*maps at levels of 2.5 σ and 1 σ respectively. The structure suggests that the enzyme can selectively bind conformer (a*S*)-**1a** and subsequent hydride attack would lead directly to the lowest energy product conformer (*R*,a*S*)-**2a**.

**Table 3**. Biotransformations with improved *Asp*RedAm and *Ao*IRED variants.



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Conversion of substrate/%, *ee*/% (*R* or *S*) | | | |
| IRED | **1a** | **1b** | **1c** | **1d** |
| *Asp*RedAm WT | >99, >99 (*R*) | 98 | 5 | 0 |
| *Asp*RedAm Q240A | >99, >99 (*R*) | >99 | 67, 7 (*S*) | 8 |
| *Asp*RedAm M214A | 92, >99 (*R*) | >99 | 17, 30 (*R*) | 0 |
| *Asp*RedAm W210A | 95, >99 (*R*) | >99 | 7, 9 (*R*) | 0 |
| *Ao*IRED WT | 51, >99 (*R*) | 5 | <1 | 0 |
| *Ao*IRED N241A | 22, 92 (*R*) | 23 | 23, 40 (*R*) | 0 |
| *Ao*IRED N241C | 5 | >99 | 16, 7 (*R*) | 0 |

Reaction conditions: 5 mM 7, 0.5 mg/mL purified IRED, 0.4 mg/mL glucose dehydrogenase CDX-901(GDH), 20 mM glucose, NADP+ (0.3 mM), 100 mM NaP*i* buffer, pH 7.0, 30°C, 250 rpm, 24 h. WT = wild-type. † Conversion and *ee* determined by HPLC or GC-FID analysis on a chiral phase.

Mutagenesis of another enzyme, *Ao*IRED, was also investigated by performing alanine-scanning site-directed mutagenesis of amino acid residues within 8 Å of the ligand binding site. The single-point mutants generated (N171A, L175A, M178A, Y179A, N241A, T244A, Y282A and Y283A) were screened for activity towards (±)-**1c** in whole-cell biotransformations. The M178A and N241A variants displayed good activity towards (±)-**1c** with N241A showing higher conversion (23%). Attempts to further expand the binding pocket did not improve the efficiency of these variants as the double mutants M178A/N241A and Y179A/N241A afforded lower conversion when compared to N241A. Interestingly, residue Q240 in *Asp*RedAm and N241 in *Ao*IRED are in analogous positions within their respective active sites and mutagenesis studies showed that alanine variants at these positions were the most successful for improving activity towards (±)-**1c** and (±)-**1d**. Therefore, this position is potentially an important target for expanding the substrate scope of IREDs/RedAms towards bulkier substrates.

The preparation of chiral imine (*S*)-**1c** in single enantiomer form was achieved with the aid of TA biocatalysts ATA-113 and Pc-SpuC from *P. chlororaphis* subsp. *aureofaciens*[38] for the synthesis of the intermediate (*S*)-**7** from ketone **6** in high yield and enantioselectivity (Scheme 2). Imine (*S*)-**1c** is a versatile intermediate for the synthesis of various dibenz[*c*,*e*]azepine frameworks such as **8** *via* nucleophilic attack onto the imine.[39] This route could also provide access to compound **2d** which was not possible in high conversion with IRED catalysis. (*S*)-**1c** was also reduced chemically with NaBH4 to afford enantiopure (*S*,a*R*)-**2a** (major conformer), providing an alternative to the IRED biocatalytic route to this compound (Scheme 2).



**Scheme 2**. Synthesis of (*S*)-**1c** employing transaminase biocatalysts ATA-113 and Pc-SpuC.

In summary, we have demonstrated the synthetic utility of IRED and transaminase biocatalysts for the preparation of enantiomerically pure dibenz[*c*,*e*]azepine frameworks. By screening a range of IRED biocatalysts, several enantiocomplementary enzymes were highlighted with preparative-scale reactions successfully carried out in high yield and enantiomeric excess. For the first time, a dibenz[*c*,*e*]azepine imine has been crystallised in the active site of an IRED by employing the redox inactive cofactor NADPH4 which informed mutagenesis studies by rational design. Furthermore transaminase biocatalysis has enabled the synthesis of enantiopure precursors of 5,7-disubstituted dibenz[*c*,*e*]azepine compounds.

**Acknowledgements**

S.P.F. acknowledges a CASE award from the UK Biotechnology and Biological Sciences Research Council (BBSRC) and Pfizer. M.S. and J.M.S were funded by grant BB/M006832/1 from the BBSRC. R.W.A. acknowledges an EPSRC core capability grant K039547/1 for NMR equipment. I.S. acknowledges a CASE award from BBSRC and Dr Reddy’s (Grant code BB/K013076/1). N.J.T. acknowledges the ERC for the award of an Advanced Grant. Thanks also go to Oliver J. Dunks for assistance with chemical synthesis and to Dr. Nicholas J. Weise for insightful discussions.

**Experimental Section**

See supporting information.

Keywords: dibenz[*c*,*e*]azepines • biocatalysis • biocatalytic retrosynthesis • imine reductase • transaminase

**References**

[1] L. R. M. De, M. Y. Berlin, J. Zheng, R. G. Aslanian, K. D. McCormick, Q. Zeng, *Tricyclic Heterocycle Derivatives as Histamine H3 Antagonists, WO2010011653 A1*, **2010**.

[2] I. H. Hall, A. R. K. Murthy, S. D. Wyrick, *J. Pharm. Sci.* **1986**, *75*, 622–626.

[3] P. C. B. Page, C. J. Bartlett, Y. Chan, D. Day, P. Parker, B. R. Buckley, G. A. Rassias, A. M. Z. Slawin, S. M. Allin, J. Lacour, et al., *J. Org. Chem.* **2012**, *77*, 6128–6138.

[4] T. Kano, H. Sugimoto, K. Maruoka, *J. Am. Chem. Soc.* **2011**, *133*, 18130–18133.

[5] L. A. Saudan, G. Bernardinelli, E. P. Kundig, *Synlett* **2000**, *4*, 483–486.

[6] S. L. Pira, T. W. Wallace, J. P. Graham, *Org. Lett.* **2009**, *11*, 1663–1666.

[7] C. A. Cheetham, R. S. Massey, S. L. Pira, R. G. Pritchard, T. W. Wallace, *Org. Biomol. Chem.* **2011**, *9*, 1831–1838.

[8] S. Postikova, M. Sabbah, D. Wightman, N. Ich Tuan, M. Sanselme, T. Besson, J.-F. Briere, S. Oudeyer, V. Levacher, *J. Org. Chem.* **2013**, *78*, 8191–8197.

[9] P. C. B. Page, C. A. Pearce, Y. Chan, P. Parker, B. R. Buckley, G. A. Rassias, M. R. J. Elsegood, *J. Org. Chem.* **2015**, *80*, 8036–8045.

[10] V. Narbonne, P. Retailleau, G. Maestri, M. Malacria, *Org. Lett.* **2014**, *16*, 628–631.

[11] N. J. Turner, E. O’Reilly, *Nat. Chem. Biol.* **2013**, *9*, 285–288.

[12] A. P. Green, N. J. Turner, *Perspect. Sci.* **2016**, *9*, 42–48.

[13] M. Hönig, P. Sondermann, N. J. Turner, E. M. Carreira, *Angew. Chem. Int. Ed.* **2017**, DOI: 10.1002/anie.201612462.

[14] F. Guo, P. Berglund, *Green Chem.* **2017**, *19*, 333–360.

[15] S. Mathew, H. Yun, *ACS Catal.* **2012**, *2*, 993–1001.

[16] D. Koszelewski, K. Tauber, K. Faber, W. Kroutil, *Trends Biotechnol.* **2010**, *28*, 324–332.

[17] R. C. Simon, N. Richter, E. Busto, W. Kroutil, *ACS Catal.* **2014**, *4*, 129–143.

[18] J. Mangas-Sanchez, S. P. France, S. L. Montgomery, G. A. Aleku, H. Man, M. Sharma, J. I. Ramsden, G. Grogan, N. J. Turner, *Curr. Opin. Chem. Biol.* **2017**, *37*, 19–25.

[19] G. Grogan, N. J. Turner, *Chem. Eur. J.* **2016**, *22*, 1900–1907.

[20] J. H. Schrittwieser, S. Velikogne, W. Kroutil, *Adv. Synth. Catal.* **2015**, *357*, 1655–1685.

[21] F. Leipold, S. Hussain, S. P. France, N. J. Turner, in *Sci. Synth. Biocatal. Org. Synth. Vol 2* (Eds.: K. Faber, W.-D. Fessner, N.J. Turner), Georg Thieme Verlag, Stuttgart, **2015**, pp. 359–382.

[22] G. A. Aleku, S. P. France, H. Man, J. Mangas-Sanchez, S. L. Montgomery, M. Sharma, F. Leipold, S. Hussain, G. Grogan, N. J. Turner, *Nat. Chem.* **2017**, DOI:10.1038/nchem.2782.

[23] M. J. Abrahamson, E. Vazquez-Figueroa, N. B. Woodall, J. C. Moore, A. S. Bommarius, *Angew. Chem. Int. Ed.* **2012**, *51*, 3969–3972.

[24] L. J. Ye, H. H. Toh, Y. Yang, J. P. Adams, R. Snajdrova, Z. Li, *ACS Catal.* **2015**, *5*, 1119–1122.

[25] F. Parmeggiani, N. J. Weise, S. T. Ahmed, N. J. Turner, *Chem. Rev.* **2017**, DOI: 10.1021/acs.chemrev.6b00824.

[26] E. Busto, V. Gotor-Fernández, V. Gotor, *Chem. Rev.* **2011**, *111*, 3998–4035.

[27] I. Alfonso, V. Gotor, *Chem. Soc. Rev.* **2004**, *33*, 201–209.

[28] D. Ghislieri, A. P. Green, M. Pontini, S. C. Willies, I. Rowles, A. Frank, G. Grogan, N. J. Turner, *J. Am. Chem. Soc.* **2013**, *135*, 10863–10869.

[29] K. Yasukawa, S. Nakano, Y. Asano, *Angew. Chem. Int. Ed.* **2014**, *53*, 4428–4431.

[30] R. S. Heath, M. Pontini, B. Bechi, N. J. Turner, *ChemCatChem* **2014**, *6*, 996–1002.

[31] S. Hussain, F. Leipold, H. Man, E. Wells, S. P. France, K. R. Mulholland, G. Grogan, N. J. Turner, *ChemCatChem* **2015**, *7*, 579–583.

[32] F. Leipold, S. Hussain, D. Ghislieri, N. J. Turner, *ChemCatChem* **2013**, *5*, 3505–3508.

[33] S. P. France, S. Hussain, A. M. Hill, L. J. Hepworth, R. M. Howard, K. R. Mulholland, S. L. Flitsch, N. J. Turner, *ACS Catal.* **2016**, *6*, 3753–3759.

[34] M. Gand, H. Müller, R. Wardenga, M. Höhne, *J. Mol. Catal. B Enzym.* **2014**, *110*, 126–132.

[35] D. Wetzl, M. Berrera, N. Sandon, D. Fishlock, M. Ebeling, M. Müller, S. Hanlon, B. Wirz, H. Iding, *ChemBioChem* **2015**, *16*, 1749–1756.

[36] S. P. France, R. M. Howard, J. Steflik, N. J. Weise, J. Mangas-Sanchez, S. L. Montgomery, R. Crook, R. Kumar, N. J. Turner, *ChemCatChem* **2017**, DOI:10.1002/cctc.201701408.

[37] G. A. Aleku, H. Man, S. P. France, F. Leipold, S. Hussain, L. Toca-, R. Marchington, S. Hart, J. P. Turkenburg, G. Grogan, et al., *ACS Catal.* **2016**, *6*, 3880–3889.

[38] J. L. Galman, I. Slabu, N. J. Weise, C. Iglesias, F. Parmegianni, R. C. Lloyd, N. J. Turner, *Green Chem.* **2017**, *19*, 361–366.

[39] M. Tichý, M. Buděšínský, J. Gűnterová, J. Závada, J. Podlaha, I. Císařová, *Tetrahedron* **1999**, *55*, 7893–7906.

**Entry for the Table of Contents**

Layout 2:

|  |  |  |
| --- | --- | --- |
| COMMUNICATION | | |
| Biocatalytic retrosynthetic analysis of dibenz[c,e]azepines highlighted the use of imine reductase (IRED) and ω-transaminase (ω-TA) biocatalysts to establish key stereocentres. Several enantiocomplementary IREDs were identified for the synthesis of enantiopure dibenz[c,e]azepines. Crystallographic evidence suggests that IREDs may be able to bind one atropisomer of the imine substrate. ω-TA biocatalysts also enabled an orthogonal route for the installation of chirality.  ***ω*-TA**  **Biocatalytic Retrosynthesis**  **IRED**  Up to >99% *ee*  Up to 95% isolated yield  >99% *ee*  Up to 86% isolated yield  R1 = H, Me; R2 = H, Me |  | Scott P. France, Godwin A. Aleku, Mahima Sharma, Juan Mangas-Sanchez, Roger M. Howard, Jeremy Steflik, Rajesh Kumar, Ralph W. Adams, Iustina Slabu, Robert Crook, Gideon Grogan, Timothy W. Wallace, and Nicholas J. Turner\*  Page No. – Page No.  Biocatalytic Routes to Enantiomerically Pure Dibenz[c,e]azepines |
|  |